In this phase 2 study, patients with advanced NSCLC harbouring sensitizing EGFR and T790M mutations in plasma at progression from ≥one 1G/2G TKI were treated with 80 mg of Osimertinib daily until progression. During the treatment, ctDNA clearance at Cycle 3 (C3) showed improved PFS...
In the phase 3 PROpel trial, a significant improvement in overall survival is observed for olaparib with abiraterone compared to placebo with abiraterone in patients with mCRPC. The improvement observed was primarily attributable to patients with BRCA mutation. ( Ref: Saad F, et al. Lancet...
In the phase 2 CAPRI trial, patients with recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient high-grade serous ovarian cancer (HGSOC) and clinically benefited from PARPi before progression, treated with ceralasertib (ATR inhibitor) and olaparib (PARP inhibitor) showed ORR of 50% (95% confidence interval,...
In the KEYNOTE-B61 phase 2, single-arm study, patients with previously untreated stage IV non-clear-cell renal cell carcinoma treated with pembrolizumab plus lenvatinib showed a confirmed objective response (49%; 95% CI 41-57), including confirmed complete response (6%) and partial response (44%). The most common Grade 3-4...
In single-arm, phase 2 RAGNAR study, treatment with erdafitinib (selective pan-FGFR tyrosine kinase inhibitor) showed clinical benefit in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. An objective response was observed in 64 (30%...
In the Phase III study in 708 patients with HR–positive, HER2-negative advanced breast cancer who progressed during or after aromatase inhibitor therapy, the combination of AKT inhibitor capivasertib and fulvestrant showed significantly longer progression-free survival than with fulvestrant alone, both in the overall population (HR:...